

# Information for Connecticut Prescribers of Prescription Drugs

## REYVOW® (lasmiditan tablets CV)

- Connecticut Public Act No. 23-171 requires “pharmaceutical representatives” (as defined in the Act) provide certain information to prescribers and pharmacists. The information in this disclosure is being provided pursuant to this Act.
- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.

### Product:

BRAND NAME	GENERIC NAME	STRENGTH	DOSAGE FORM	PACK SIZE	NDC	WHOLESALE ACQUISITION COST <sup>1</sup>
REYVOW®	lasmiditan tablets CV	50 mg	Tablet	8	0002-4312-08	\$740.88
		100 mg	Tablet	8	0002-4491-08	\$740.88

REYVOW® is a registered trademark owned or licensed by Eli Lilly and Company, its subsidiaries or affiliates.

---

<sup>1</sup> Source: AnalySource®. Accessed on 11/01/2025. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2025. <http://www.fdbhealth.com/policies/drug-pricing-policy/>.